Mid-Sized Pharmas Mostly Seeing Valuations Rise During Pandemic

The novel coronavirus pandemic is bringing pressure across the breadth of the biopharmaceutical industry, from big pharmas to biotech. Square in the middle are mid-size firms, a tier that includes big biotechs and specialty companies, which face unique pressures due to smaller and less diversified product portfolios than larger firms.

However, for several mid-sized firms, the pandemic also is providing opportunity, and all but one of the companies reviewed by...